Wednesday, 19 October 2016 09:30 AM
TAMPA, FL / ACCESSWIRE / October 19, 2016 / Morphogenesis, Inc., a biotechnology company headquartered in Tampa, FL, announces its plans to raise up to $20 million from the sale of its common stock to accredited investors. The company is not only embracing new securities industry rules, it is launching what it hopes to be a uniquely efficient capital raising process made possible by the confluence of social and technological changes.
"We couldn't be more excited about this offering!" says Dr. Patricia Lawman, CEO of Morphogenesis. "Rather than pages of hardcopy, we have created an interactive digital offering that allows for easy access to pertinent information with informative videos and animations throughout."
Morphogenesis, a privately-held biotechnology company specializing in cell and gene therapies, has developed multi-indication immunotherapies which educates the patient's own immune system to attack tumor cells throughout the body without damaging normal cells or tissues. "We decided that since Morphogenesis is a high tech company in all aspects of its business, why not take advantage of the multi-communication channels digital marketing provides to create a free-flowing, non-linear, cross platform investor experience," says Dr. Lawman. "Our intent is to leverage our experience, knowledge and relationships in the evolving digital environment so that we can focus less time on capital raising and more time ensuring that our innovative technologies are made available to millions of cancer victims worldwide."
Morphogenesis' wholly-owned subsidiary, Veterinary Oncology Services, Inc., (www.veterinaryoncologyservices.com) provides IFx-VET (www.ifx-vet.com), a personalized form of ImmuneFx, to veterinarians across the U.S. for dogs, cats and horses with many different types of cancers. The immunotherapy will soon be in trials for human patients with indolent non-Hodgkin lymphoma and melanoma, with future plans for pancreatic and breast cancer trials. The funds being raised through this offering will be used for these human trials and for the launch of its direct injectable cancer vaccine, IFx-VETDirect, into the veterinary market.
The digital offering can be found on the homepage of Morphogenesis (www.morphogenesis-inc.com) under "Invest in Morphogenesis" or you can email a request to [email protected] for more information. This release is not intended to be an offer to sell or the solicitation of an offer to buy securities. Investing in our securities involves a high degree of risk, and requires high risk tolerance, low liquidity concerns, and long-term commitments, such that investors should be able to bear the loss of their investment.
SOURCE: Morphogenesis, Inc.